Hui Huang1, Suyue Zheng2, Mingwei Lu3. 1. Department of Neurosurgery, the Second Affiliated Hospital of Nanchang University, Nanchang City, Jiangxi Province, PR, 330006, China. 2. Department of Neurosurgery, the First Affiliated Hospital of Nanchang University, Nanchang, PR, 330006, China. 3. Department of Neurosurgery, the Second Affiliated Hospital of Nanchang University, Nanchang City, Jiangxi Province, PR, 330006, China. mingweilujiangxi@163.com.
Abstract
BACKGROUND: Long non-coding RNA (lncRNA) MEG3 regulates human cancers, while its role in Parkinson's disease (PD) is unknown. The present study explored the involvement of MEG3 in PD. METHODS: This study enrolled PD patients (n = 79) and healthy controls (n = 62) who were admitted to the Second Affiliated Hospital of Nanchang University from May 2016 to March 2018. RT-qPCR was performed to measure the expression of MEG3 and LRRK2. ROC curve analysis was performed for diagnostic analysis. Cell transfections were performed to analyze the interaction between MEG3 and LRRK2. Cell apoptosis and MTT assays were performed to evaluate the effect of cell transfections on cell apoptosis and viability. RESULTS: MEG3 was downregulated in PD patients compared to that in the healthy controls. ROC curve analysis showed altered expression of MEG3 in PD patients. MEG3 was also down-regulated in SH-SY5Y cells treated with MPP + . Overexpression of MEG3 increased the expression levels of leucine-rich repeat kinase 2 (LRRK2) in SH-SY5Y cells. In contrast, overexpression of LRRK2 showed no significant effects on MEG3. Overexpression of MEG3 improved the viability and inhibited the apoptosis of SH-SY5Y cells pretreated with MPP + . CONCLUSIONS: In conclusion, lncRNA MEG3 is downregulated in PD and may affect the expression of LRRK2 to regulate cell viability and apoptosis involved in PD.
BACKGROUND: Long non-coding RNA (lncRNA) MEG3 regulates human cancers, while its role in Parkinson's disease (PD) is unknown. The present study explored the involvement of MEG3 in PD. METHODS: This study enrolled PD patients (n = 79) and healthy controls (n = 62) who were admitted to the Second Affiliated Hospital of Nanchang University from May 2016 to March 2018. RT-qPCR was performed to measure the expression of MEG3 and LRRK2. ROC curve analysis was performed for diagnostic analysis. Cell transfections were performed to analyze the interaction between MEG3 and LRRK2. Cell apoptosis and MTT assays were performed to evaluate the effect of cell transfections on cell apoptosis and viability. RESULTS: MEG3 was downregulated in PD patients compared to that in the healthy controls. ROC curve analysis showed altered expression of MEG3 in PD patients. MEG3 was also down-regulated in SH-SY5Y cells treated with MPP + . Overexpression of MEG3 increased the expression levels of leucine-rich repeat kinase 2 (LRRK2) in SH-SY5Y cells. In contrast, overexpression of LRRK2 showed no significant effects on MEG3. Overexpression of MEG3 improved the viability and inhibited the apoptosis of SH-SY5Y cells pretreated with MPP + . CONCLUSIONS: In conclusion, lncRNA MEG3 is downregulated in PD and may affect the expression of LRRK2 to regulate cell viability and apoptosis involved in PD.
Authors: D Lin; Y Liang; X Jing; Y Chen; M Lei; Z Zeng; T Zhou; X Wu; S Peng; D Zheng; K Huang; L Yang; S Xiao; J Liu; E Tao Journal: Brain Res Date: 2017-11-12 Impact factor: 3.252
Authors: Xianming Deng; Nicolas Dzamko; Alan Prescott; Paul Davies; Qingsong Liu; Qingkai Yang; Jiing-Dwan Lee; Matthew P Patricelli; Tyzoon K Nomanbhoy; Dario R Alessi; Nathanael S Gray Journal: Nat Chem Biol Date: 2011-03-06 Impact factor: 15.040